Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT

European Heart Journal

Volumn 38, Issue 17, 2017, Pages 1339-1344

  Van Gelder, Isabelle C ^a   Healey, Jeff S ^b   Crijns, Harry J G M ^c   Wang, Jia ^b   Hohnloser, Stefan H ^d   Gold, Michael R ^e   Capucci, Alessandro ^f   Lau, Chu Pak ^g   Morillo, Carlos A ^b   Hobbelt, Anne H ^a   Rienstra, Michiel ^a   Connolly, Stuart J ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b MCMASTER UNIVERSITY   (Canada)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d GOETHE UNIVERSITY   (Germany)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^f UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^g UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL OUTCOME; DISEASE DURATION; DUAL CHAMBER PACEMAKER; EMBOLISM; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; INCIDENCE; INTERNAL DEFIBRILLATOR; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; TREATMENT DURATION; ARTIFICIAL HEART PACEMAKER; BODY MASS; COMPLICATION; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; KAPLAN MEIER METHOD; MORTALITY; RISK FACTOR; TREATMENT OUTCOME;

AGED; ATRIAL FIBRILLATION; BODY MASS INDEX; BRAIN ISCHEMIA; DEFIBRILLATORS, IMPLANTABLE; EMBOLISM; FEMALE; HUMANS; HYPERTENSION; KAPLAN-MEIER ESTIMATE; MALE; PACEMAKER, ARTIFICIAL; RISK FACTORS; STROKE; TREATMENT OUTCOME;

EID: 85019459154     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehx042     Document Type: Article

References (32)

1. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener H-C, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: the Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2016;37:2893-2962.
2. Vermond RA, Geelhoed B, Verweij N, Tieleman RG, Van der Harst P, Hillege HL, Van Gilst WH, Van Gelder IC, Rienstra M. Incidence of atrial fibrillation and relationship with cardiovascular events, heart failure, and mortality: a communitybased study from the Netherlands. J Am Coll Cardiol 2015;66:1000-1007.
3. Levy S, Maarek M, Coumel P, Guize L, Lekieffre J, Medvedowsky JL, Sebaoun A. Characterization of different subsets of atrial fibrillation in general practice in France: ALFA study. The College of French Cardiologists. Circulation 1999;99:3028-3035.
4. Kerr CR, Humphries KH, Talajic M, Klein GJ, Connolly SJ, Green M, Boone J, Sheldon R, Dorian P, Newman D. Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: results from the Canadian Registry of Atrial Fibrillation. Am Heart J 2005;149:489-496.
5. Tsang TS, Barnes ME, Miyasaka Y, Cha SS, Bailey KR, Verzosa GC, Seward JB, Gersh BJ. Obesity as a risk factor for the progression of paroxysmal to permanent atrial fibrillation: a longitudinal cohort study of 21 years. Eur Heart J 2008;29:2227-2233.
6. Nieuwlaat R, Prins MH, Le Heuzey JY, Vardas PE, Aliot E, Santini M, Cobbe SM, Widdershoven JW, Baur LH, Levy S, Crijns HJ. Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation. Eur Heart J 2008;29:1181-1189.
7. de Vos CB, Pisters R, Nieuwlaat R, Prins MH, Tieleman RG, Coelen RJ, van den Heijkant AC, Allessie MA, Crijns HJ. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol 2010;55:725-731.
8. Camm AJ, Breithardt G, Crijns H, Dorian P, Kowey P, Le Heuzey JY, Merioua I, Pedrazzini L, Prystowsky EN, Schwartz PJ, Torp-Pedersen C, Weintraub W. Real-life observations of clinical outcomes with rhythm-and rate-control therapies for atrial fibrillation RECORDAF (Registry on Cardiac Rhythm Disorders Assessing Control of Atrial Fibrillation). J Am Coll Cardiol 2011;58:493-501.
9. Smit MD, Maass AH, De Jong AM, Muller Kobold AC, Van Veldhuisen DJ, Van Gelder IC. Role of inflammation in early atrial fibrillation recurrence. Europace 2012;14:810-817.
10. De Vos CB, Breithardt G, Camm AJ, Dorian P, Kowey PR, Le Heuzey JY, Naditch-Brule L, Prystowsky EN, Schwartz PJ, Torp-Pedersen C, Weintraub WS, Crijns HJ. Progression of atrial fibrillation in the REgistry on Cardiac rhythm disORDers assessing the control of Atrial Fibrillation cohort: clinical correlates and the effect of rhythm-control therapy. Am Heart J 2012;163:887-893.
11. Zhang YY, Qiu C, Davis PJ, Jhaveri M, Prystowsky EN, Kowey P, Weintraub WS. Predictors of progression of recently diagnosed atrial fibrillation in REgistry on Cardiac Rhythm DisORDers Assessing the Control of Atrial Fibrillation (RecordAF)-United States cohort. Am J Cardiol 2013;112:79-84.
12. Vidal-Perez R, Otero-Ravina F, Lado-Lopez M, Turrado-Turrado V, Rodriguez-Moldes E, Gomez-Vazquez JL, de Frutos-de Marcos C, de Blas-Abad P, Besada-Gesto R, Gonzalez-Juanatey JR. The change in the atrial fibrillation type as prognosis marker in a community study: long-term data from AFBAR (Atrial Fibrillation in the BARbanza) study. Int J Cardiol 2013;168:2146-2152.
13. Akutsu Y, Kaneko K, Kodama Y, Miyoshi F, Li HL, Watanabe N, Asano T, Tanno K, Suyama J, Namiki A, Gokan T, Kobayashi Y. A combination of P wave electrocardiography and plasma brain natriuretic peptide level for predicting progression to persistent atrial fibrillation: comparisons of sympathetic activity and left atrial size. J Interv Cardiac Electrophysiol 2013;38:79-84.
14. De Sisti A, Leclercq JF, Halimi F, Fiorello P, Bertrand C, Attuel P. Evaluation of time course and predicting factors of progression of paroxysmal or persistent atrial fibrillation to permanent atrial fibrillation. PACE 2014;37:345-355.
15. Vanassche T, Lauw MN, Eikelboom JW, Healey JS, Hart RG, Alings M, Avezum A, Diaz R, Hohnloser SH, Lewis BS, Shestakovska O, Wang J, Connolly SJ. Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirintreated patients in ACTIVE-A and AVERROES. Eur Heart J 2014;36:281-27a.
16. Steinberg BA, Hellkamp AS, Lokhnygina Y, Patel MR, Breithardt G, Hankey GJ, Becker RC, Singer DE, Halperin JL, Hacke W, Nessel CC, Berkowitz SD, Mahaffey KW, Fox KA, Califf RM, Piccini JP, The ROCKET-AF Steering Committee and Investigators. Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from ROCKET-AF Trial. Eur Heart J 2015;36:288-296.
17. Ganesan AN, Chew DP, Hartshorne T, Selvanayagam JB, Aylward PE, Sanders P, McGavigan AD. The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: systematic review and meta-analysis. Eur Heart J 2016;37:1591-1602.
18. Glotzer TV, Hellkamp AS, Zimmerman J, Sweeney MO, Yee R, Marinchak R, Cook J, Paraschos A, Love J, Radoslovich G, Lee KL, Lamas GA. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST). Circulation 2003;107:1614-1619.
19. Glotzer TV, Daoud EG, Wyse DG, Singer DE, Ezekowitz MD, Hilker C, Miller C, Qi D, Ziegler PD. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: TRENDS study. Circ Arrhythm Electrophysiol 2009;2:474-480.
20. Botto GL, Padeletti L, Santini M, Capucci A, Gulizia M, Zolezzi F, Favale S, Molon G, Ricci R, Biffi M, Russo G, Vimercati M, Corbucci G, Boriani G. Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for risk of thromboembolic events. J Cardiovasc Electrophysiol 2009;20:241-248.
21. Hohnloser SH, Capucci A, Fain E, Gold MR, van Gelder IC, Healey J, Israel CW, Lau CP, Morillo C, Connolly SJ. ASymptomatic atrial fibrillation and Stroke Evaluation in pacemaker patients and the atrial fibrillation Reduction atrial pacing Trial (ASSERT). Am Heart J 2006;152:442-447.
22. Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, Lau CP, Fain E, Yang S, Bailleul C, Morillo CA, Carlson M, Themeles E, Kaufman ES, Hohnloser SH. Subclinical atrial fibrillation and the risk of stroke. New Engl J Med 2012;366:120-129.
23. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-1457.
24. Snapinn SM, Jiang Q, Iglewicz B. Illustrating the impact of a time-varying covariate with an extended Kaplan-Meier estimator. Am Stat 2005;59:301-307.
25. Dafni U. Landmark analysis at the 25-year landmark point. Circ Cardiovasc Qual Outcomes 2011;4:363-371.
26. Emdin CA, Anderson SG, Salimi-Khorshidi G, Woodward M, MacMahon S, Dwyer T, Rahimi K. Usual blood pressure, atrial fibrillation and vascular risk: evidence from 4.3 million adults. Int J Epidemiol 2016;pii:dyw053. [doi: 10.1093/ije/dyw053]
27. Capucci A, Santini M, Padeletti L, Gulizia M, Botto G, Boriani G, Ricci R, Favale S, Zolezzi F, Di Belardino N, Molon G, Drago F, Villani GQ, Mazzini E, Vimercati M, Grammatico A. Italian AT500 Registry Investigators. Monitored atrial fibrillation duration predicts arterial embolic events in patients suffering from bradycardia and atrial fibrillation implanted with antitachycardia pacemakers. J Am Coll Cardiol 2005;46:1913-1920.
28. Daoud EG, Glotzer TV, Wyse DG, Ezekowitz MD, Hilker C, Koehler J, Ziegler PD. Temporal relationship of atrial tachyarrhythmias, cerebrovascular events, and systemic emboli based on stored device data: a subgroup analysis of TRENDS. Heart Rhythm 2011;8:1416-1423.
29. Brambatti M, Connolly SJ, Gold MR, Morillo CA, Capucci A, Muto C, Lau C, Van Gelder IC, Hohnloser SH, Carlson M, Fain E, Nakamya J, Mairesse GH, Halytska M, Deng WQ, Israel CW, Healey JS. Temporal relationship between subclinical atrial fibrillation and embolic events. Circulation 2014;129:2094-2099.
30. Turakhia MP, Ziegler PD, Schmitt SK, Chang Y, Fan J, Than CT, Keung EK, Singer DE. Atrial fibrillation burden and short-term risk of stroke: case-crossover analysis of continuously recorded heart. Rhythm from cardiac electronic implanted devices. Circ Arrhythm Electrophysiol 2015;8:1040-1047.
31. Martin DT, Bersohn MM, Waldo AL, Wathen MS, Choucair WK, Lip GY, Ip J, Holcomb R, Akar JG, Halperin JL, Impact Investigators. Randomized trial of atrial arrhythmia monitoring to guide anticoagulation in patients with implanted defibrillator and resynchronization devices. Eur Heart J 2015;36:1660-1668.
32. Li N, Chiang DY, Wang S, Wang Q, Sun L, Voigt N, Respress JL, Ather S, Skapura DG, Jordan VK, Horrigan FT, Schmitz W, Muller FU, Valderrabano M, Nattel S, Dobrev D, Wehrens XH. Ryanodine-receptor mediated calcium leak drives progressive development of an atrial fibrillation substrate in a transgenic mouse model. Circulation 2014;129:1276-1285.